For research use only. Not for therapeutic Use.
MAPK13-IN-1（Cat No.:I019987）is a selective inhibitor of MAPK13, also known as p38δ, a member of the p38 MAPK family involved in cellular responses to stress and inflammation. By targeting MAPK13, this inhibitor helps regulate pathways related to inflammation, cell differentiation, and apoptosis. MAPK13-IN-1 is particularly useful in research focused on diseases where p38δ plays a role, such as inflammatory conditions, autoimmune disorders, and certain cancers. Its selectivity allows researchers to explore the specific effects of MAPK13 inhibition, making it a valuable tool for developing targeted therapies.
| Catalog Number | I019987 |
| CAS Number | 229002-10-2 |
| Molecular Formula | C₂₀H₂₃N₅O₂ |
| Purity | ≥95% |
| IUPAC Name | 1-(5-tert-butyl-2-methylpyrazol-3-yl)-3-(4-pyridin-4-yloxyphenyl)urea |
| InChI | InChI=1S/C20H23N5O2/c1-20(2,3)17-13-18(25(4)24-17)23-19(26)22-14-5-7-15(8-6-14)27-16-9-11-21-12-10-16/h5-13H,1-4H3,(H2,22,23,26) |
| InChIKey | MHSLDASSAFCCDO-UHFFFAOYSA-N |
| SMILES | CC(C)(C)C1=NN(C(=C1)NC(=O)NC2=CC=C(C=C2)OC3=CC=NC=C3)C |
| Reference | [1]. Yurtsever Z, et al. First comprehensive structural and biophysical analysis of MAPK13 inhibitors targeting DFG-in and DFG-out binding modes. Biochim Biophys Acta. 2016 Nov;1860(11 Pt A):2335-2344.<br>[2]. Mehdi Bouhaddou, et al. The Global Phosphorylation Landscape of SARS-CoV-2 Infection. Cell. 2020 Aug 6;182(3):685-712.e19. |
